CD8+ cytotoxic T cells are the primary participants driving the adaptive immune response against cancer and executing a tumor-specific immune response; therefore, CD8+ cytotoxic T cells are the primary endpoints of immunotherapy (Spitzer et al., 2017; Ostroumov et al., 2018). The gene discussed is CD8A; the disease is cancer.